Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550104 | 0.89 | SIGMAR1 (0.59) | BCHESIGMAR1KMT2ACA1CA2 | |
| SCHEMBL2483554 | 0.89 | SIGMAR1 (0.59) | BCHESIGMAR1KMT2ACA1CA2 | |
| SCHEMBL11076410 | 0.84 | BCHE (0.56) | BCHEL3MBTL1TDP1SIGMAR1MEN1 | |
| SCHEMBL719011 | 0.82 | SIGMAR1 (0.74) | BCHEL3MBTL1TDP1SIGMAR1MEN1 | |
| SCHEMBL593666 | 0.82 | SIGMAR1 (0.74) | BCHEL3MBTL1TDP1SIGMAR1MEN1 | |
| SCHEMBL2795948 | 0.82 | SIGMAR1 (0.74) | BCHEL3MBTL1TDP1SIGMAR1MEN1 | |
| SCHEMBL8092326 | 0.82 | SIGMAR1 (0.74) | BCHEL3MBTL1TDP1SIGMAR1MEN1 | |
| SCHEMBL2717201 | 0.81 | TACR1 (0.53) | MEN1KMT2AHTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL1134233 | 0.81 | SIGMAR1 (0.72) | BCHEL3MBTL1TDP1SIGMAR1MEN1 | |
| Hydrochloric Acid SCHEMBL1134234 | 0.81 | SIGMAR1 (0.72) | BCHEL3MBTL1TDP1SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088923-B2 | Cyclic-fused beta-lactones and their synthesis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090062547-A1 | CYCLIC-FUSED BETA-LACTONES AND THEIR SYNTHESIS | THE TEXAS A&M UNIVERSITY SYSTEM | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062547-A1 | CYCLIC-FUSED BETA-LACTONES AND THEIR SYNTHESIS | COASY, FASN, OTUB1 | BCHE 373/4885L3MBTL1 1736/4885TDP1 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.